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dssociation of a Nonsynonymous Variant ofDAOAwith
isuospatial Ability in a Bipolar Family Sample
ia Soronen, Kaisa Silander, Mervi Antila, Outi M. Palo, Annamari Tuulio-Henriksson, Tuula Kieseppä,
ekka Ellonen, Juho Wedenoja, Joni A. Turunen, Olli P.H. Pietiläinen, William Hennah, Jouko Lönnqvist,
eena Peltonen, Timo Partonen, and Tiina Paunio
ackground: Bipolar disorder and schizophrenia are hypothesized to share some genetic background.
ethods: In a two-phase study, we evaluated the effect of five promising candidate genes for psychotic disorders, DAOA, COMT, DTNBP1,
RG1, and AKT1, on bipolar spectrum disorder, psychotic disorder, and related cognitive endophenotypes in a Finnish family-based sample
scertained for bipolar disorder.
esults: In initial screening of 362 individuals from 63 families, we found only marginal evidence for association with the diagnosis-based
ichotomous classification. Those associations did not strengthen when we genotyped the complete sample of 723 individuals from 180
amilies. We observed a significant association of DAOA variants rs3916966 and rs2391191 with visuospatial ability (Quantitative Transmis-
ion Disequilibrium Test [QTDT]; p  4  106 and 5  106, respectively) (n  159) with the two variants in almost complete linkage
isequilibrium. The COMT variant rs165599 also associated with visuospatial ability, and in our dataset, we saw an additive effect of DAOA
nd COMT variants on this neuropsychological trait.
onclusions: The ancestral allele (Arg) of the nonsynonymous common DAOA variant rs2391191 (Arg30Lys) was found to predispose to
mpaired performance. The DAOA gene may play a role in predisposing individuals to a mixed phenotype of psychosis and mania and to
mpairments in related neuropsychological traits.ey Words: AKT1, bipolar disorder, COMT, DAOA, DTNBP1, G72,
europsychological trait, NRG1
ipolar disorder (BPD) is a severe mental disorder charac-
terized by alternating episodes of depression and mania
(bipolar type I [BPD-I]) or hypomania (bipolar type II
BPD-II]). Certain cognitive impairments such as poor executive
unctioning and verbal memory have been related to disease
usceptibility (1). Despite being considered distinct clinical dis-
rders, BPD and schizophrenia share many clinical features and
reatment approaches. Sixty percent of BPD-I patients have
sychotic symptoms during their lifetime (2). Bipolar disorder
nd schizophrenia co-segregate in many pedigrees (3), which
uggest a shared genetic etiology of these two disorders at least
o some extent.
In our previous study, we found evidence for contribution of
istinct variants of the disrupted-in-schizophrenia 1 (DISC1)
ene to features of bipolar spectrum and psychotic disorders in
innish families ascertained for BPD (4). We screened the same
et of BPD families for several promising candidate genes for
sychotic disorders: d-amino acid oxidase activator (DAOA or
72) (5), catechol-O-methyl transferase (COMT) (6), dystrobre-
in binding protein 1 (dysbindin or DTNBP1) (7), neuregulin 1
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oi:10.1016/j.biopsych.2008.03.028(NRG1) (8), and v-akt murine thymoma viral oncogene homolog
1 (AKT1) (9). Except for AKT1, these genes have been reported
to associate with various neuropsychological traits within af-
fected individuals or healthy control subjects (Supplement 1). We
evaluated the effects of variations in these genes both on clinical
diagnosis of bipolar spectrum disorder or psychotic disorder, as
well as on cognitive functions considered as endophenotypes (or
intermediate traits) for these disorders (10).
Methods andMaterials
Study Sample
The study sample includes 723 individuals from 180 families
(4) (Table 1); neuropsychological test data were available alto-
gether for 159 individuals from 65 of the families (11) (Table 1).
Ascertainment strategy and sample collection are described in
Supplement 2. The study was approved by the Ministry of Social
Affairs and Health and the Ethical Committee of the National
Public Health Institute.
Single Nucleotide Polymorphism Selection and Genotyping
We selected single nucleotide polymorphisms (SNPs) from
published findings (5-9) and from the public SNP database,
dbSNP (http://www.ncbi.nlm.nih.gov). Genotyping was done
with homogeneous mass extension using the MassARRAY Sys-
tem (Sequenom, San Diego, California) in multiplexes of two to
six SNPs. The COMT variants were genotyped by microarray-
based allele-specific primer extension method (12). Genotyping
was performed in two phases. Phase I was an initial screening
involving 362 individuals from 63 families. In phase II, we
examined an additional 361 individuals from 117 families.
Statistical Analysis
Association analyses using dichotomized diagnostic classes
(bipolar spectrum disorder and psychotic disorder) were per-
formed by haplotype relative risk (HRR) test of the ANALYZE
package (13) for two-point analyses and by FBAT (14) for
BIOL PSYCHIATRY 2008;64:438–442
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P. Soronen et al. BIOL PSYCHIATRY 2008;64:438–442 439aplotype analyses. Unaffected family members and individuals
ith other mental disorders were coded as unknown. Analyses
ere done using two different sample sets, the first including all
ndividuals genotyped and the second including only familial
ases, defined as cases from families with two or more affected
embers. We used the Quantitative Transmission Disequilibrium
est (QTDT) software package (15) with the polygenic variance
omponent option and performed association analyses of quan-
itative traits with the total association model assuming no
opulation stratification. Age, gender, and presence of psychosis
16) were used as covariates. Statistical comparisons of the
esults in different genotyped groups and diagnostic categories
ere analyzed by SPSS 14.0 (SPSS Inc., Chicago, Illinois) using
ne-way analysis of variance (ANOVA). Interaction analysis was
one by logistic regression backward stepwise model.
able 1. Number of Individuals in Phase I and Phase II of the Study and
he Total Number of Familial Cases
Phase I Phase II
Familial
CasesaFemale Male Female Male
ffected 78 (32) 89 (30) 65 (4) 84 (14) 258
Bipolar spectrum
disorderb 59 (29) 68 (24) 50 (4) 50 (9) 173
Psychotic disorderc 66 (27) 65 (25) 51 (4) 69 (12) 212
In both categoriesd 47 (24) 44 (19) 36 (4) 35 (7) 127
Other mental disordere 22 (14) 12 (8) 5 (2) 7 (3) 45
naffected 92 (29) 69 (21) 116 (1) 84 (1) 241
otal Genotyped 192 (75) 170 (59) 186 (7) 175 (18) 544
The number of neuropsychologically tested individuals is shown in pa-
entheses.
BPD-I, bipolar disorder type I; BPD-II, bipolar disorder type II; NOS, not
therwise specified.
aThe familial cases are from 118 families with more than one affected
ndividual.
bContains BPD-I (n 214), BPD-II (n 5), bipolar disorder NOS (n 6),
nd cyclothymia (n 2) cases.
cContains BPD-I with intermittent psychotic features (n  162), psy-
hotic depression (n 15), schizophrenia (n 14), schizoaffective disorder
n 51), and psychotic NOS (n 9). Numbers are from the whole sample.
dOverlap between bipolar spectrum and psychotic disorder categories.
eContains depression, alcohol-, related disorders and delusional, adjust-
ent, dysthymic, and panic disorders.
able 2. Association Between Single SNP and Disease Status in Phase I, Co
Bipolar Spectrum Disorder
Phase I
(62 Families)
Phase I II
(154 Families)
Famili
(99 F
AOA
rs3916966 .696 .966 .
rs2391191 .889 .913 .
rs2153674 .072 .353 .
rs701567 .670 .593 .
rs778326 .025 .111 .
rs954580 .040 .107 .
OMT
rs4680 .085 .046 .
rs165599 .003 .829 .
COMT, catechol-O-methyl transferase; DAOA, d-amino acid oxidase activ
aFamilial cases include only families that contain at least two affected individResults
We initially screened 51 SNPs of the selected genes (Supplement
3) in 362 individuals from 63 families (Table 1). The most significant
association of dichotomized phenotype was obtained for COMT
variant rs165599 with bipolar spectrum disorder (HRR; p  .003)
(Supplement 3). Adjacent 2-SNP haplotype analysis showed no
evidence for association with either bipolar spectrum or psychotic
disorder (Supplement 4). Several DAOA variants were associated
with neuropsychological traits (Supplement 5). The strongest asso-
ciations were seen between DAOA variants rs3916966 and
rs2391191 (Arg30Lys) and visuospatial ability assessed with the
Block Design test (p  .0006 and p .0008, respectively).
We focused our analysis on DAOA and COMT and genotyped
all 723 individuals from 180 families using six DAOA variants
(rs3916966, rs2391191, rs2153674, rs701567, rs778326, and
rs954580) and two COMT variants (rs165599 and rs4680, also
known as valine [Val]158 methionine [Met]).
In the complete sample, the COMT variant rs4680 was the
only variant that associated with bipolar spectrum disorder in the
complete sample (Table 2). In the familial sample, both rs4680
and rs165599 showed suggestive evidence of association with
bipolar spectrum disorder. D-amino acid oxidase activator
(DAOA) variants rs701567 and rs778326 were suggestively asso-
ciated with psychotic disorder in the familial sample. For both
genes, analysis of 2-SNP haplotypes yielded no further evidence
of association (data not shown).
Analysis of the full study sample strengthened the previously
observed association between DAOA variants rs3916966 and
rs2391191 (Arg30Lys) and visuospatial ability (Table 3). These
two variants are in almost perfect linkage disequilibrium (r2 
.98). Visuospatial performance differed significantly between the
Arg and Lys genotype groups of rs2391191, with the worst
performance observed in individual homozygotes for the ances-
tral G (Arg) allele (Table 4, Figure 1). All study subjects perform-
ing above the average, i.e., achieving over 40 points in the Block
Design test (n  27), were either homozygous or heterozygous
for the A (Lys) allele.
Catechol-O-methyl transferase (COMT ) variant rs165599 asso-
ciated with visuospatial ability. Individuals homozygous for the
G allele had the best test performance among the rs165599
genotype groups. This difference was statistically significant in
the full sample and in the psychotic subgroup but not in the
nonpsychotic subgroup (Table 4).
ed Phase I and Phase II, and Familial Cases Using HRR Analysis
Psychotic Disorder
esa
s)
Phase I
(57 Families)
Phase I II
(144 Families)
Familial Casesa
(102 Families)
.843 .839 .616
.87 .891 .349
.066 .700 .233
.278 .133 .031
.010 .186 .018
.049 .565 .252
.340 .072 .149
.015 .396 .103
HRR, haplotype relative risk; SNP, single nucleoide polymorphism.mbin
al Cas
amilie
906
735
095
407
024
052
020
035
ator;
uals.
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wAs shown in Table 4, individuals homozygous for both the
ncestral allele G (Arg) of DAOA variant rs2391191 and the T
llele of COMT variant rs165599 performed worse in the Block
esign test (mean test score  15.6) than did subjects homozy-
ous only for the DAOA rs2391191 G allele (mean test score 
4.8) or the COMT rs165599 T allele (mean test score  28.6).
owever, backward stepwise logistic regression showed no
vidence for significant interaction between the two variants
p  .5 for rs2391191*rs165599). Decreased test performance in
he doubly homozygous subjects suggests a minor additive effect
f DAOA and COMT variants on visuospatial ability, without
vidence for epistasis.
iscussion
D-amino acid oxidase activator (DAOA) is a primate-specific
ene encoding mitochondrial protein that promotes mitochon-
rial fragmentation and dendritic branching (17). D-amino acid
xidase activator (DAOA) may be involved in glutamate signaling
5), which has been shown to have multiple effects on learning
nd memory (18). Like some other genes encoding mitochon-
rial proteins in primates, the DAOA gene has evolved rapidly;
he open reading frame of the human gene is twice as long as
hat of the chimpanzee homolog (5).
The strongest finding of our study was the association of a
onsynonymous DAOA variant, rs2391191 (Arg30Lys), with
isuospatial ability, which remains significant after a conservative
onferroni correction for multiple testing (corrected p .005). In
recent study (19), the Arg allele associated with impairment in
mmediate and delayed verbal memory. In the present study, this
llele showed only a trend for association with verbal memory
able 3. Association Between Neuropsychological Traits and Candidate Ge
europsychological Trait rs3916966 rs
eneral Intellectual Functioning (WAIS-R)
General ability (Vocabulary) .0015 .
Abstraction (Similarities) .0010 .
Psychomotor speed (Digit Symbol) .0013 .
Visuospatial ability (Block Design) 4.00E-06a 5.
ttention, Working Memory (WMS-R)
Auditory attention (Digit Span forward) .0091 .
Verbal working memory (Digit Span backward) .0298 .
Visual attention (Visual Span forward) .1899 .
Visual working memory (Visual Span backward) .7120 .
erbal and Visual Memory (WMS-R)
Immediate verbal memory (Logical Memory I) .1176 .
Delayed verbal memory (Logical Memory II) .1076 .
Immediate visual memory (Visual Reproduction I) .0047 .
Delayed visual memory (Visual Reproduction II) .0005 .
erbal Learning and Memory (CVLT)
Free short delay recall .0032 .
Free long delay recall .0443 .
Recognition memory .0173 .
Retention .9571 .
xecutive Functions
Stroop Interference score .0162 .
Semantic fluency (COWAT) .0195 .
Phonemic fluency (COWAT) .4183 .
COMT, catechol-O-methyl transferase; COWAT, Controlled Oral Word As
ctivator; WAIS-R, Wechsler Adult Intelligence Scale-Revised; WMS-R, Wechs
ap values that remained significant (p .05) after conservative Bonferrop  0.1), but it predisposed to impairment with many other
ww.sobp.org/journalcognitive traits, most significantly with visuospatial ability. Thus,
our data further strengthen the possibility that the Arg30Lys
variation might affect cognitive functioning. Interestingly, the Lys
allele that associated here with enhanced performance in the
tests of general intellectual functioning is found only in humans,
suggesting that DAOA might have played a part in the evolution
of Homo sapiens when greater cognitive functions developed as
the brain increased in size.
Catechol-O-methyl transferase (COMT) variant rs4680 (Val158Met)
associated here nominally with familial bipolar spectrum disor-
der, but the risk allele (Met) was different from that reported by
Figure 1. Block Design test results for DAOA rs2391191 genotype groups.
Average values of nonpsychotic individuals (white bars) and individuals
with psychotic disorder (gray bars) are shown. Also, the standard deviation
ariants Genotyped in the Combined Sample Using QTDT Analysis
DAOA COMT
91 rs2153674 rs701567 rs954580 rs4680 rs165599
.0086 .0083 .0051 .1381 .1801
.0063 .0173 .1428 .1191 .2103
.0953 .0125 .2591 .0986 .0051
6a .0638 .0108 .0392 .0191 .0007
.0991 .1948 .0724 .2769 .5932
.1089 .4111 .6239 .4017 .8425
.6787 .2073 .2443 .8875 .9947
.9652 .7439 .5356 .7039 .4952
.4636 .7139 .7698 .9536 .8925
.8161 .5091 .4862 .5853 .4035
.2174 .2841 .1352 .0628 .1468
.2658 .1316 .2061 .1200 .2613
.0537 .1016 .1397 .0891 .4644
.2987 .5264 .7442 .0054 .0570
.1617 .4569 .5709 .1076 .4686
.4304 .8079 .2869 .0391 .0016
.3567 .0047 .3510 .3090 .7938
.8410 .0168 .3594 .5887 .4003
.0369 .4284 .4841 .6706 .5438
ion Test; CVLT, California Verbal Learning Test;DAOA, d-amino acid oxidase
emory Scale-Revised; QTDT, Quantitative Transmission Disequilibrium Test.
rrection.ne V
23911
0002
0003
0034
00E-0
0088
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sociatbar is shown. DAOA, d-amino acid oxidase activator.
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P. Soronen et al. BIOL PSYCHIATRY 2008;64:438–442 441Shifman et al. (6). Variant rs165599 was also associated with
visuospatial ability, with the best test performance seen in
individuals homozygous for the C allele. An earlier study
showed association of the COMT variant rs165599 with verbal
memory in Caucasians (20), but better performance was
associated with the T allele. The incoherence in findings on
the effect of COMT on neuropsychological performance likely
results from a relatively weak effect and the genetic hetero-
geneity behind these traits.
We found a minor additive effect of DAOA and COMT on
visuospatial ability, a finding consistent with the hypothesis
that interaction of glutamatergic (DAOA) and dopaminergic
(COMT) neurotransmission is fundamental for many cognitive
functions, particularly working memory (18). We recognize
that all neuropsychological traits assessed in the present study
may be state-dependent; however, many of the observed
deviations are also found in euthymic BPD patients (1).
Furthermore, our finding of association of DAOA with visuo-
spatial ability did not result from an underlying effect of DAOA
genotype to other illness-related parameters, such as medica-
tion or age of onset (data not shown). While there are no data
for visuospatial ability being a good endophenotype for BPD,
there is at least one study that showed impaired general
intellectual function in relatives of psychotic patients (21).
Other DAOA variants also associated weakly with psychotic
disorder. The DAOA gene may play a role in predisposing
individuals to a mixed phenotype of psychosis and mania and
to impairments in related neuropsychological traits. However,
further research is necessary to define the effect of DAOA on
the complex processes of brain functions.
This study was funded by The Academy of Finland for TPau
(Nr 203425).
We thank all the individuals who participated in this study.
Liisa Arala, Minna Suvela, and Sisko Lietola are acknowledged
for excellent technical assistance.
All authors reported no biomedical financial interests or
potential conflicts of interest.
Supplementary material cited in this article is available
online.
1. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier
IN, et al. (2006): A meta-analysis of cognitive deficits in euthymic pa-
tients with bipolar disorder. J Affect Disord 93:105–115.
2. Goodwin FK, Jamison KR (2007): Manic-Depressive Illness. Bipolar Disor-
ders andRecurrentDepression, 2nded.NewYork:OxfordUniversityPress.
3. Valles V, Van Os J, Guillamat R, Gutierrez B, Campillo M, Gento P, et al.
(2000): Increasedmorbid risk for schizophrenia in families of in-patients
with bipolar illness. Schizophr Res 42:83–90.
4. Palo OM, Antila M, Silander K, Hennah W, Kilpinen H, Soronen P, et al.
(2007): Association of distinct allelic haplotypes of DISC1with psychotic
and bipolar spectrum disorders and with underlying cognitive impair-
ments. HumMol Genet 16:2517–2528.
5. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M,
Abderrahim H, et al. (2002): Genetic and physiological data implicating
the new human gene G72 and the gene for D-amino acid oxidase in
schizophrenia. Proc Natl Acad Sci U S A 99:13675–13680.
6. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman
E, Weizman A, et al. (2002): A highly significant association between
a COMT haplotype and schizophrenia. Am J Hum Genet 71:1296–
1302.
7. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al.
(2002): Genetic variation in the 6p22.3 gene DTNBP1, the human or-
tholog of the mouse dysbindin gene, is associated with schizophrenia.
Am J HumGenet 71:337–348.Ta
b
C
O
C
O
V
ar
C
C
C
T
TT M
e
p
v
www.sobp.org/journal
11
1
1
1
1
442 BIOL PSYCHIATRY 2008;64:438–442 P. Soronen et al.
w8. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sig-
mundsson T, Ghosh S, et al. (2002): Neuregulin 1 and susceptibility to
schizophrenia. Am J HumGenet 71:877–892.
9. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004):
Convergent evidence for impaired AKT1-GSK3beta signaling in schizo-
phrenia. Nat Genet 36:131–137.
0. Gottesman II, Gould TD (2003): The endophenotype concept in psychi-
atry: Etymology and strategic intentions. Am J Psychiatry 160:636–645.
1. AntilaM, Tuulio-HenrikssonA, KieseppaT, SoronenP, PaloOM,PaunioT,
et al. (2007): Heritability of cognitive functions in families with bipolar
disorder. Am JMed Genet B Neuropsychiatr Genet 144:802–808.
2. Silander K, Komulainen K, Ellonen P, Jussila M, Alanne M, Levander M,
et al. (2005): Evaluating whole genome amplification via multiply-
primed rolling circle amplification for SNP genotyping of samples with
low DNA yield. Twin Res Hum Genet 8:368–375.
3. Terwilliger JD, Ott J (1992): A haplotype-based ’haplotype relative risk’
approach to detecting allelic associations. Hum Hered 42:337–346.
4. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM (2004):
Family-based tests for associating haplotypes with general phenotype
data: Application to asthma genetics. Genet Epidemiol 26:61–69.5. Abecasis GR, Cardon LR, CooksonWO (2000): A general test of association
for quantitative traits in nuclear families.Am JHumGenet 66:279–292.
ww.sobp.org/journal16. Keshavan MS, Rabinowitz J, DeSmedt G, Harvey PD, Schooler N (2004):
Correlates of insight in first episode psychosis. Schizophr Res 70:187–
194.
17. Kvajo M, Dhilla A, Swor DE, Karayiorgou M, Gogos JA (2007): Evidence
implicating the candidate schizophrenia/bipolar disorder susceptibility
gene G72 in mitochondrial function. [published online ahead of print
August 7, 2007].Mol Psychiatry.
18. Castner SA, Williams GV (2007): Tuning the engine of cognition: A focus
on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 63:
94–122.
19. Donohoe G, Morris DW, Robertson IH, McGhee KA, Murphy K, Kenny N,
et al. (2007): DAOA ARG30LYS and verbal memory function in schizo-
phrenia.Mol Psychiatry 12:795–796.
20. Burdick KE, Funke B, Goldberg JF, Bates JA, Jaeger J, Kucherlapati R,
et al. (2007): COMT genotype increases risk for bipolar I disorder
and influences neurocognitive performance. Bipolar Disord 9:370–
376.
21. Zinkstok JR, de Wilde O, van Amelsvoort TA, Tanck MW, Baas F, Linszen
DH (2007): Association between the DTNBP1 gene and intelligence: A
case-control study in young patients with schizophrenia and related
disorders and unaffected siblings. Behav Brain Funct 3:19.
